α 2-adrenoceptor regulation of blood glucose homeostasis

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 6, 2011, Pages 365-370

  Fagerholm, Veronica ^a   Haaparanta, Merja ^a   Scheinin, Mika ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ATIPAMEZOLE; BETA ADRENERGIC RECEPTOR; GLUCOSE; INSULIN; NEUROLEPTIC AGENT; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CHROMAFFIN CELL; DRUG POTENTIATION; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SHORT SURVEY; SYMPATHETIC TONE;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; RECEPTORS, ADRENERGIC, ALPHA-2; SULFONYLUREA COMPOUNDS;

CANIS FAMILIARIS;

EID: 79955977849     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00699.x     Document Type: Short Survey

References (50)

1. Brede M, Philipp M, Knaus A, Muthig V, Hein L. Alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. Biol Cell 2004;96:343-8.
2. Moura E, Afonso J, Hein L, Vieira-Coelho MA. Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 2006;149:1049-58.
3. Chan SL, Perrett CW, Morgan NG. Differential expression of alpha 2-adrenoceptor subtypes in purified rat pancreatic islet A- and B-cells. Cell Signal 1997;9:71-8.
4. Lacey RJ, Chan SL, Cable HC, James RF, Perrett CW, Scarpello JH et al. Expression of alpha 2- and beta-adrenoceptor subtypes in human islets of Langerhans. J Endocrinol 1996;148:531-43.
5. Angel I, Niddam R, Langer SZ. Involvement of alpha-2 adrenergic receptor subtypes in hyperglycemia. J Pharmacol Exp Ther 1990;254:877-82.
6. Niddam R, Angel I, Bidet S, Langer SZ. Pharmacological characterization of alpha-2 adrenergic receptor subtype involved in the release of insulin from isolated rat pancreatic islets. J Pharmacol Exp Ther 1990;254:883-7.
7. Peterhoff M, Sieg A, Brede M, Chao CM, Hein L, Ullrich S. Inhibition of insulin secretion via distinct signaling pathways in alpha2-adrenoceptor knockout mice. Eur J Endocrinol 2003;149:343-50.
8. Hu X, Friedman D, Hill S, Caprioli R, Nicholson W, Powers AC et al. Proteomic exploration of pancreatic islets in mice null for the alpha2A adrenergic receptor. J Mol Endocrinol 2005;35:73-88.
9. Fagerholm V, Grönroos T, Marjamäki P, Viljanen T, Scheinin M, Haaparanta M. Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice. Eur J Pharmacol 2004;505:243-52.
10. Regard JB, Kataoka H, Cano DA, Camerer E, Yin L, Zheng YW et al. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J Clin Invest 2007;117:4034-43.
11. Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor knockout mice. Eur J Pharmacol 2008;578:359-64.
12. Klein C, Morton N, Kelley S, Metz S. Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose. J Hypertens Suppl 1985;3:S81-4.
13. Lattermann R, Schricker T, Georgieff M, Schreiber M. Low dose clonidine premedication accentuates the hyperglycemic response to surgery. Can J Anaesth 2001;48:755-9.
14. Parsons WB Jr, Morledge JH. Antihypertensive effect of a new imidazoline compound (clonidine) and chlorthalidone, individually and in combination. Am J Cardiol 1970;26:258-61.
15. Barbieri C, Caldara R, Testori G, Piepoli V, Trezzi R, Romussi M et al. Oral glucose tolerance and insulin response after one week's clonidine treatment in hypertensive patients. Acta Diabetol Lat 1981;18:59-63.
16. Guthrie GP Jr, Miller RE, Kotchen TA, Koenig SH. Clonidine in patients with diabetes and mild hypertension. Clin Pharmacol Ther 1983;34:713-7.
17. Kimber J, Sivenandan M, Watson L, Mathias CJ. Age- and gender-related growth hormone responses to intravenous clonidine in healthy adults. Growth Horm IGF Res 2001;11:128-35.
18. Joffe BI, Haitas B, Edelstein D, Panz V, Lamprey JM, Baker SG et al. Clonidine and the hormonal responses to graded exercise in healthy subjects. Horm Res 1986;23:136-41.
19. Nishina K, Mikawa K, Maekawa N, Shiga M, Obara H. Effects of oral clonidine premedication on plasma glucose and lipid homeostasis associated with exogenous glucose infusion in children. Anesthesiology 1998;88:922-7.
20. Giugliano D, Acampora R, Marfella R, La Marca C, Marfella M, Nappo F et al. Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1998;11:184-9.
21. Nilsson-Ehle P, Ekberg M, Fridström P, Ursing D, Lins LE. Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine. Acta Med Scand 1988;224:131-4.
22. Stornello M, Valvo EV, Scapellato L, Nazzari M. Humoral and hemodynamic effects of nitrendipine versus clonidine in patients with essential hypertension. Clin Ther 1986;8:510-9.
23. Burge MR, Kamin JR, Timm CT, Qualls CR, Schade DS. Low-dose epinephrine supports plasma glucose in fasted elderly patients with type 2 diabetes. Metabolism 2000;49:195-202.
24. Devedjian JC, Pujol A, Cayla C, George M, Casellas A, Paris H et al. Transgenic mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered regulation of glucose homeostasis. Diabetologia 2000;43:899-906.
25. Hamamdzic D, Duzic E, Sherlock JD, Lanier SM. Regulation of alpha 2-adrenergic receptor expression and signaling in pancreatic beta-cells. Am J Physiol 1995;269:E162-71.
26. Davani B, Portwood N, Bryzgalova G, Reimer MK, Heiden T, Östenson CG et al. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes 2004;53(Suppl 1):S51-9.
27. Rosmond R, Bouchard C, Björntorp P. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med 2002;251:252-7.
28. Boesgaard TW, Grarup N, Jørgensen T, Borch-Johnsen K, Hansen T, Pedersen O. Variants at DGKB/TMEM195, ADRA2A, GLIS3 and C2CD4B loci are associated with reduced glucose-stimulated beta cell function in middle-aged Danish people. Diabetologia 2010;53:1647-55.
29. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-16.
30. Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010;327:217-20.
31. Small KM, Brown KM, Seman CA, Theiss CT, Liggett SB. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. Proc Natl Acad Sci USA 2006;103:5472-7.
32. Berlin I, Rosenzweig P, Chalon S, Fuseau E, Landault C, Cesselin F et al. Reduction of hyperglycemia after oral glucose load by the new alpha 2-adrenergic receptor antagonist SL 84.0418 in healthy subjects. Clin Pharmacol Ther 1994;55:338-45.
33. Buse MG, Johnson AH, Kuperminc D, Buse J. Effect of alpha-adrenergic blockade on insulin secretion in man. Metabolism 1970;19:219-25.
34. Kawazu S, Suzuki M, Negishi K, Watanabe T, Ishii J. Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjects. Diabetes 1987;36:216-20.
35. Ortiz-Alonso FJ, Herman WH, Gertz BJ, Williams VC, Smith MJ, Halter JB. Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus. Metabolism 1991;40:1160-7.
36. Robertson RP, Halter JB, Porte D Jr. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 1976;57:791-5.
37. Schmidt ME, Goldstein DS, Schouten JL, Matochik JA, Kim HG, Potter WZ. Acute alpha 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomography. Psychopharmacol Bull 1997;33:253-9.
38. Ribes G, Trimble ER, Blayac JP, Wollheim CB, Loubatieres-Mariani MM. In vivo stimulation of pancreatic hormone secretion by norepinephrine infusion in the dog. Am J Physiol 1984;246:E339-43.
39. Östenson CG, Pigon J, Doxey JC, Efendic S. Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes. J Clin Endocrinol Metab 1988;67:1054-9.
40. Natali A, Gastaldelli A, Galvan AQ, Sironi AM, Ciociaro D, Sanna G et al. Effects of acute alpha 2-blockade on insulin action and secretion in humans. Am J Physiol 1998;274:E57-64.
41. Sciberras DG, Reed JW, Elliott C, Blain PG, Goldberg MR. The effects of a peripherally selective alpha 2-adrenoceptor antagonist, MK-467, on the metabolic and cardiovascular response to exercise in healthy man. Br J Clin Pharmacol 1994;37:39-44.
42. Morgan NG, Chan SL. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 2001;7:1413-31.
43. Efendic S, Efanov AM, Berggren PO, Zaitsev SV. Two generations of insulinotropic imidazoline compounds. Diabetes 2002;51(Suppl 3):S448-54.
44. Fagerholm V, Scheinin M, Haaparanta M. Alpha2a-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice. Br J Pharmacol 2008;154:1287-96.
45. Khosravi M, Oryan S, Haeri Rohani SA, Parivar K, Marandi R. Control of environmental health and removal of rats by alpha2-adrenergic antagonist and potassium channel blocker. Iran J Environ Health Sci Eng 2006;3:255-60.
46. Berridge TL, Doxey JC, Roach AG. Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. Eur J Pharmacol 1992;213:213-8.
47. Mourtada M, Brown CA, Smith SA, Piercy V, Chan SL, Morgan NG. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion. Br J Pharmacol 1997;121:799-805.
48. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(Suppl 4):19-25.
49. Garcia-Sevilla JA, Hollingsworth PJ, Smith CB. Alpha 2-adrenoreceptors on human platelets: selective labelling by [3H]clonidine and [3H]yohimbine and competitive inhibition by antidepressant drugs. Eur J Pharmacol 1981;74:329-41.
50. Kalkman HO, Loetscher E. Alpha2c-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 2003;462:33-40.